Respiratory Research (Oct 2019)

Insufficient serum L-ficolin is associated with disease presence and extent of pulmonary Mycobacterium avium complex disease

  • Tomofumi Kobayashi,
  • Koji Kuronuma,
  • Atsushi Saito,
  • Kimiyuki Ikeda,
  • Shigeru Ariki,
  • Atsushi Saitou,
  • Mitsuo Otsuka,
  • Hirofumi Chiba,
  • Satoshi Takahashi,
  • Motoko Takahashi,
  • Hiroki Takahashi

DOI
https://doi.org/10.1186/s12931-019-1185-9
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background The incidence of infectious disease caused by nontuberculous mycobacteria is increasing worldwide. Pulmonary Mycobacterium avium complex (MAC) disease is difficult to treat with chemotherapy, and its mechanism of infection, infection route, disease onset, and severity remain unknown. Ficolins are oligomeric defense lectins. L-ficolin plays an important role in innate immunity. This study’s aim was to identify L-ficolin’s role in patients with pulmonary MAC disease. Methods Between April 2011 and September 2017, 61 Japanese patients with pulmonary MAC disease were seen at our hospital. A control group, comprising 30 healthy individuals, without respiratory disease were enrolled in our study. The relationship between serum L-ficolin levels and disease severity was assessed, and L-ficolin’s antibacterial role was examined. Results Serum L-ficolin levels were significantly lower in patients with pulmonary MAC disease than in healthy subjects (1.69 ± 1.27 μg/ml vs. 3.96 ± 1.42 μg/ml; p < 0.001). The cut-off value, based on receiver operating characteristic (ROC) analysis results, was 2.48 μg/ml (area under the curve (AUC) 0.90, sensitivity and specificity 83.6 and 86.7%, respectively). Serum L-ficolin levels were significantly lower in the patients with nodular bronchiectatic type disease compared with the patients with fibrocavitary type disease and were lower in the high-resolution computed tomography high-scoring group compared with low-scoring group. An in vitro analysis showed that purified recombinant L-ficolin bound to M. avium and its major cell wall component, lipoarabinomannan, in a concentration-dependent manner. In addition, recombinant L-ficolin suppressed M. avium growth in a concentration-dependent manner. Conclusions Insufficient serum L-ficolin is associated with disease progression in pulmonary MAC disease, and the level of serum L-ficolin is a possible biomarker. Trial registration This study is registered with UMIN (UMIN000022392).

Keywords